We are what we repeatedly do. Excellence, then, is not an act, but a habit.

— Will Durant

PNA Medical Corner: MRI for Cushing’s

7T MRI for Cushing’s Disease: A Single Institutional Experience and Literature Review

PMID: 38365424   DOI: 10.3174/ajnr.A8209

Abstract

Background and purpose: Cushing disease is typically caused by a pituitary adenoma that frequently is small and challenging to detect on conventional MRI. High field strength 7T MRI can leverage increased signal-to-noise and contrast-to-noise ratios compared to lower-field strength MRI to help identify small pituitary lesions. We aim to describe our institutional experience with 7T MRI in patients with Cushing disease and perform a review of the literature.

Materials and methods: A retrospective analysis of 7T MRI findings in patients with pathology proven cases of Cushing disease from a single institution, followed by a review of the literature on 7T MRI for Cushing disease.

Results: Our institutional experience identified Cushing adenomas in 10/13 (76.9%) patients on 7T, however only 5/13 (38.5%) lesions were discrete. Overall, the imaging protocols used were heterogeneous in terms of contrast dose as well as type of post-contrast T1-weighted sequences (Dynamic, 2D vs 3D, and type of 3D sequence). From our institutional data, specific post-gadolinium T1-weighted sequences were helpful in identifying a surgical lesion as follows: Dynamic Contrast Enhanced 2/7 (28.6%), 2D FSE 4/8 (50%), 3D SPACE 5/6 (83.3%), and 3D MPRAGE 8/11 (72.7%). The literature review identified Cushing adenomas in 31/33 (93.9%) patients on 7T.

Conclusions: 7T MRI for pituitary lesion localization in Cushing disease is a new technique with imaging protocols that varied widely. Further comparative research is needed to identify the optimal imaging technique as well as to assess the benefit of 7T over lower-field strength MRI.

Abbreviations: MRI = Magnetic Resonance Imaging, CT = Computed Tomography, 7T = 7 Tesla, DCE = Dynamic Contrast Enhanced.

© 2024 by American Journal of Neuroradiology.

    Featured News and Updates

    News Articles June 2025

    News Articles June 2025

    New imaging tool to diagnose Cushing’s?

    An article in Cushing’s Disease News looks at a study that find that a new form of PET scan, alongside a CT  scans can detect tumors that produce ACTH, common in Cushing’s disease. Read more:

    https://cushingsdiseasenews.com/news/imaging-technique-found-accurately-id-cushings-pituitary-tumors/

    Exercise and hormonal health

    An article in mindbodygreen.com examines the effect of exercise on your hormones. Read more: https://www.mindbodygreen.com/articles/how-high-intensity-exercise-impacts-cortisol-and-other-hormones

    Pituitary patient describes afterlife following near-death experience

    A story on MSN.com relates the experiences of Brianna Lafferty, a pituitary patient who was clinically dead for 8 minutes. She now works as a transition guide. Read more here:

    https://www.msn.com/en-us/health/medical/woman-who-died-for-8-minutes-claims-death-is-an-illusion-as-she-recalls-afterlife/ar-AA1FuWo5

    Research Articles

    June 2025 Research Articles

    Pituitary Tumors

    Effect of antineoplastic drug therapies on carcinoma and aggressive pituitary tumors: a systematic review and meta-analysis.

    Cardoso ABR, Zimmermann AC, Raverot G, Nunes-Nogueira VDS.Pituitary. 2025 Jun 2;28(3):70. doi: 10.1007/s11102-025-01541-0.

    Impulse control disorders in pituitary adenoma: What do we know and what we still don’t know in almost two decades?

    Kadioglu P, Glezer A.Pituitary. 2025 Jun 2;28(3):71. doi: 10.1007/s11102-025-01533-0.

    Effect of antineoplastic drug therapies on carcinoma and aggressive pituitary tumors: a systematic review and meta-analysis.

    Cardoso ABR, Zimmermann AC, Raverot G, Nunes-Nogueira VDS.Pituitary. 2025 Jun 2;28(3):70. doi: 10.1007/s11102-025-01541-0. 

    Impulse control disorders in pituitary adenoma: What do we know and what we still don’t know in almost two decades?

    Kadioglu P, Glezer A.Pituitary. 2025 Jun 2;28(3):71. doi: 10.1007/s11102-025-01533-0.

    Clinico-pathological and molecular characteristics of pediatric-juvenile pituitary neuroendocrine tumors (PitNETs): A mono-institutional series.

    Buccoliero AM, Giunti L, Ponticelli A, Innocenti L, Ricci F, Cetica V, Tirinnanzi B, Moscardi S, Stagi S, Sardi I, Mussa F, Genitori L, Scagnet M.Clin Neuropathol. 2025 Jun 2. doi: 10.5414/NP301685. Online ahead of print.

    Pituitary Surgery


    Use of a Septal Stapler to Secure a Septal Free Mucosal Graft to the Nasoseptal Flap Donor Site Following Endoscopic Endonasal Resection of a Pituitary Adenoma.

    Miller JE, Fischer JL, Wang MB.J Neurol Surg Rep. 2025 Apr 23;86(2):e98. doi: 10.1055/a-2531-6140. eCollection 2025 Apr.

    Hormonal health

    The effect of MDMA on anterior pituitary hormones: a secondary analysis of a randomized placebo-controlled trial.

    Atila C, Camerin SJ, Liechti ME, Christ-Crain M.Endocr Connect. 2025 Jun 1:EC-25-0254. doi: 10.1530/EC-25-0254. Online ahead of print.

    Combined pituitary hormone deficiency with a novel GLI2 frameshift variant.

    Matsuo Y, Adachi N, Mukai T, Kato S, Kato M, Tanaka H.Pediatr Int. 2025 Jan-Dec;67(1):e70082. doi: 10.1111/ped.70082.PMID: 40457737 No abstract available.

    Effect of pubertal induction with combined gonadotropin therapy on testes development and spermatogenesis in males with gonadotropin deficiency: a cohort study.

    Castro S, Ng Yin K, d’Aniello F, Alexander EC, Connolly E, Hughes C, Martin L, Prasad R, Storr HL, Willemsen RH, Dunkel L, Butler G, Howard SR.Hum Reprod Open. 2025 May 13;2025(2):hoaf026. doi: 10.1093/hropen/hoaf026. eCollection 2025.

    Long-term pituitary function following transsphenoidal surgery for non-functional pituitary neuroendocrine tumor with apoplexy: a single-center retrospective analysis.

    Zou D, Yang Y, Gao R, Ou Y, Luo J, Zhang Z, Yang T, Cheng J.Sci Rep. 2025 Jun 1;15(1):19226. doi: 10.1038/s41598-025-03053-0.

    Safety and efficacy of endoscopic vs. microscopic approaches in pituitary adenoma surgery: A systematic review and meta-analysis.

    Al-Dardery NM, Khaity A, Soliman Y, Ali MOM, Zedan EM, Muyasarah K, Elfakhrany MD.Neurosurg Rev. 2025 Jun 1;48(1):471. doi: 10.1007/s10143-025-03600-3.

     

    Hormonal Health

    The effect of MDMA on anterior pituitary hormones: a secondary analysis of a randomized placebo-controlled trial.

    Atila C, Camerin SJ, Liechti ME, Christ-Crain M.Endocr Connect. 2025 Jun 1:EC-25-0254. doi: 10.1530/EC-25-0254. Online ahead of print.

    Combined pituitary hormone deficiency with a novel GLI2 frameshift variant.

    Matsuo Y, Adachi N, Mukai T, Kato S, Kato M, Tanaka H.Pediatr Int. 2025 Jan-Dec;67(1):e70082. doi: 10.1111/ped.70082.

     

    The FDA has approved NGENLA (somatrogon-ghla)

    The FDA has approved NGENLA (somatrogon-ghla), a once-weekly, human growth hormone analog indicated for treatment of pediatric patients aged three years and older who have growth failure due to an inadequate secretion of endogenous growth hormone.

    See the Press Release here>

    Count on your Xeris CareConnection™ Team for unparalleled Cushing’s Support

    Cushing’s can be challenging, but there is support so patients can feel like themselves again. The main goal of treating Cushing’s is to get cortisol levels back to normal. This Pituitary Awareness Month, Xeris Pharmaceuticals® is highlighting the importance of one-on-one support for patients living with Cushing’s Syndrome and support for HCPs treating Cushing’s Syndrome.

    Sign up to get dedicated support:

    Patients: Sign up for support | Recorlev® (levoketoconazole)

    HCP’s: Connect with Xeris support | RECORLEV® (levoketoconazole)

    Have more questions? Call for more support at 1-844-444-RCLV (7258)

    Copyright © 2024 Pituitary Network Association All rights reserved.

    Disclaimer: PNA does not engage in the practice of medicine. It is not a medical authority, nor does it claim to have medical expertise. In all cases, PNA recommends that you consult your own physician regarding any course of treatment or medication.

    Our mailing address is:
    Pituitary Network Association
    P.O. Box 1958
    Thousand Oaks, CA 91358
    (805) 499-9973 Phone - (805) 480-0633 Fax
    Email [email protected]

    You are receiving this Newsletter because you have shown interest in receiving information about our activities.

    If you do not want to receive any more emails from PNA, Unsubscribe.